

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT POSSIBLE SPIN-OFF AND QUOTATION AND/OR LISTING ON A STOCK EXCHANGE IN MAINLAND CHINA

This announcement is made by the board of directors (the “**Board**”) of SSY Group Limited (the “**Company**”) on a voluntary basis.

The Board is pleased to announce that the Company is considering a possible spin-off and separate quotation and/or listing of the shares of Jiangsu Best New Medical Material Co., Ltd.* (江蘇博生醫用新材料股份有限公司) (“**Jiangsu Best New Medical**”) on a stock exchange in Mainland China. Jiangsu Best New Medical is an indirect wholly-owned subsidiary of the Company which is principally engaged in the manufacturing and sale of pharmaceutical products and medical materials (the “**Possible Spin-off**”).

If the Possible Spin-off is to proceed, it would be achieved by way of a spin-off in compliance with Practice Note 15 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). As at the date of this announcement, no application for the Possible Spin-off has been made to The Stock Exchange of Hong Kong Limited. As at the date of this announcement, no application for listing or quotation in relation to the Possible Spin-off has been made to the stock exchange in Mainland China and no final decision has been made as to whether and/or when to proceed with the Possible Spin-off.

If the Possible Spin-off is proceeded with, it may or may not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules. The Company will comply with the Listing Rules and make further announcements in connection with the Possible Spin-off as and when appropriate or required under the Listing Rules.

* *for identification purpose only*

As of the date of this announcement, the Possible Spin-off is at a preliminary stage. Shareholders of the Company and potential investors should note that the implementation of the Possible Spin-off is subject to, amongst other things, market conditions and approvals from the relevant regulatory authorities. There is no assurance when the Possible Spin-off will take place, or if it will take place at all. Accordingly, shareholders of the Company and potential investors are reminded to exercise caution when dealing in the securities of the Company.

Any person who is in doubt about his/her/its position or any action to be taken is recommended to consult his/her/its own professional adviser(s).

By order of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 18 October 2021

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.